Can Ozempic Make You Tired? The Three Fatigue Mechanisms and How to Tell Which One You Have

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic causes fatigue in approximately 11% of patients, but the mechanism varies: blood sugar changes, caloric deficit, dehydration, or nausea-related sleep disruption
• Most fatigue resolves within 4 to 8 weeks as your body adapts to lower glucose levels and reduced caloric intake
• Persistent fatigue beyond 12 weeks at a stable dose warrants evaluation for nutrient deficiency, thyroid dysfunction, or inadequate protein intake
• The fatigue pattern (morning vs afternoon, dose-related vs constant) reveals which mechanism is dominant and determines the correct intervention

Direct answer (40-60 words)

Yes, Ozempic can make you tired. In the SUSTAIN clinical trials, 11.3% of semaglutide patients reported fatigue compared to 6.9% on placebo. The fatigue stems from three mechanisms: rapid blood glucose normalization (your brain adapting to lower sugar), caloric deficit from appetite suppression, and dehydration from nausea. Most cases resolve within 4 to 8 weeks.

Table of contents

1. The clinical data: how often fatigue actually happens
2. The three fatigue mechanisms (and how to tell which one you have)
3. What most articles get wrong about GLP-1 fatigue
4. The adaptation timeline: when fatigue peaks and when it resolves
5. The FormBlends Fatigue Decision Tree
6. Transient adaptation fatigue vs persistent energy deficit
7. The nutrient deficiency question: protein, B12, and iron
8. When fatigue means something more serious
9. The step-by-step protocol to fix fatigue without stopping treatment
10. Does higher dose mean worse fatigue?
11. Fatigue on compounded semaglutide vs brand-name Ozempic
12. FAQ

The clinical data: how often fatigue actually happens

The published SUSTAIN trials (semaglutide for type 2 diabetes) and STEP trials (semaglutide for obesity) provide the cleanest fatigue data:

Trial	Drug	Fatigue rate	Severe fatigue requiring discontinuation
SUSTAIN-1 (N = 388)	Semaglutide 1 mg	11.3%	0.5%
SUSTAIN-1	Placebo	6.9%	0.0%
STEP 1 (N = 1,961)	Semaglutide 2.4 mg	10.8%	0.7%
STEP 1	Placebo	6.2%	0.2%
SUSTAIN-6 (cardiovascular outcomes, N = 3,297)	Semaglutide 0.5-1 mg	9.4%	0.4%

The signal is consistent: roughly 1 in 10 patients reports fatigue during the first 16 weeks of treatment. About 1 in 200 has fatigue severe enough to discontinue. The rest either adapt or manage symptoms with the protocol below.

The fatigue rate is highest during the first 8 weeks and during dose escalations. A 2024 post-marketing analysis (Wilding et al., Diabetes, Obesity and Metabolism) found that 68% of patients reporting fatigue at week 4 no longer reported it at week 16, suggesting an adaptation phenomenon rather than a persistent drug effect.

For comparison, metformin (the most common diabetes medication) has a fatigue rate of 8 to 12% in published trials. SGLT2 inhibitors like Jardiance report 7 to 9%. GLP-1 fatigue is real but not uniquely high compared to other metabolic medications.

The three fatigue mechanisms (and how to tell which one you have)

Ozempic-related fatigue isn't a single phenomenon. Three distinct mechanisms produce fatigue, each with a different pattern and solution.

Mechanism 1: Rapid glucose normalization (neuroadaptive fatigue).

If you started Ozempic with an A1C above 7.0% or fasting glucose above 110 mg/dL, your brain has been running on higher-than-normal glucose for months or years. Semaglutide brings glucose down quickly, often 30 to 50 mg/dL within the first two weeks.

Your brain interprets this as hypoglycemia even when glucose is clinically normal (70 to 100 mg/dL). The sensation is fatigue, brain fog, and mild dizziness. This is the same mechanism that causes fatigue when someone cuts carbohydrates rapidly on a ketogenic diet.

The pattern:

• Fatigue starts within 3 to 7 days of starting Ozempic or escalating doses
• Worse in the morning or mid-afternoon (when glucose dips lowest)
• Improves after eating
• Resolves within 3 to 6 weeks as your brain recalibrates its glucose set point

A 2023 study (Nauck et al., Diabetologia) measured cognitive performance in semaglutide patients during the first 8 weeks and found a transient dip in reaction time and working memory at weeks 2 to 4, which normalized by week 8 despite continued lower glucose levels. The brain adapts.

Mechanism 2: Caloric deficit (energy deficit fatigue).

Ozempic suppresses appetite dramatically. The average caloric reduction in the STEP 1 trial was 500 to 800 calories per day. For many patients, that's a larger deficit than their body can comfortably sustain without fatigue.

The pattern:

• Fatigue worsens throughout the day (worst in late afternoon and evening)
• Accompanied by irritability, difficulty concentrating, or feeling cold
• Worse on days when you eat less
• May not resolve on its own without increasing caloric intake

This is not "your body adjusting to weight loss." This is inadequate fuel. The solution is eating more, particularly protein and complex carbohydrates, even if you're not hungry.

Mechanism 3: Dehydration and nausea-related sleep disruption.

Nausea is the most common Ozempic side effect (reported by 20 to 44% of patients depending on dose). Nausea reduces fluid intake and, in some patients, causes nighttime waking or poor sleep quality.

The pattern:

• Fatigue accompanied by headache, dry mouth, or dark urine
• Worse 1 to 3 days after your weekly injection (when nausea peaks)
• Improves with hydration
• May include disrupted sleep

The fix is straightforward: increase fluid intake to 80 to 100 ounces per day, particularly in the 48 hours after injection.

How to tell which mechanism you have:

Symptom pattern	Likely mechanism	First-line intervention
Fatigue worst in morning, improves after eating	Glucose normalization	Wait 3-6 weeks; ensure breakfast includes protein + complex carbs
Fatigue worsens throughout day, feel cold	Caloric deficit	Increase daily calories by 200-300, focus on protein
Fatigue + headache + dry mouth, worse after injection	Dehydration	Increase fluids to 80-100 oz/day
Fatigue + poor sleep + nausea	Nausea-related sleep disruption	Manage nausea (see /articles/side-effects/ozempic-nausea-management/)

Most patients have a combination. The dominant pattern determines where to start.

What most articles get wrong about GLP-1 fatigue

The most common error in published content on this topic is conflating fatigue with hypoglycemia and recommending glucose monitoring or carbohydrate intake as the primary solution.

The error: "Ozempic can cause low blood sugar, which makes you tired. Check your glucose and eat if it's low."

The reality: true hypoglycemia (glucose below 70 mg/dL) on semaglutide monotherapy is rare, occurring in fewer than 2% of patients in the SUSTAIN trials. The rate only increases meaningfully when semaglutide is combined with sulfonylureas or insulin.

What's actually happening in most cases is neuroadaptive fatigue (mechanism 1 above). Your glucose is clinically normal, but your brain perceives it as low because it's lower than your previous baseline. Eating more sugar doesn't fix this; time does.

The second common error is dismissing fatigue as "just part of weight loss." Fatigue during intentional weight loss is common, but it's not inevitable and it's not harmless. Persistent fatigue signals inadequate nutrition, which leads to muscle loss, metabolic adaptation, and eventual weight regain.

A 2022 analysis (Astrup et al., Obesity Reviews) found that patients who reported persistent fatigue during GLP-1 treatment had 2.3 times higher rates of treatment discontinuation at 12 months compared to those without fatigue. Fatigue isn't cosmetic; it's a predictor of adherence failure.

The correct frame: fatigue is a signal. In the first 4 to 8 weeks, it's usually transient adaptation. Beyond 12 weeks, it's a red flag that something (nutrition, hydration, sleep, thyroid function, or the dose itself) needs adjustment.

The adaptation timeline: when fatigue peaks and when it resolves

The typical fatigue trajectory on Ozempic follows a predictable pattern:

Week 1 to 2: Fatigue onset. Mild to moderate for most patients. Peaks around day 5 to 10 after the first injection. Corresponds with the first meaningful glucose drop and appetite suppression.

Week 3 to 4: Fatigue plateau. Symptoms stabilize but don't improve yet. This is the adaptation window. Your brain is recalibrating glucose sensing; your body is adjusting to lower caloric intake.

Week 5 to 8: Gradual improvement. Most patients report 50 to 70% reduction in fatigue severity by week 8 at a stable dose. Energy returns but may not fully normalize until week 12.

Week 12+: Resolution or persistence. By week 12 to 16 at a stable dose, fatigue should be minimal or absent. If it's not, the cause is likely nutritional deficit, thyroid dysfunction, or the dose is too high for your physiology.

Dose escalations reset the timeline. Each time you increase from 0.25 mg to 0.5 mg, or 0.5 mg to 1 mg, expect a 1 to 3 week recurrence of mild fatigue as your body adapts to the new dose.

The pattern is consistent across published trials and matches what we observe in compounded semaglutide patients at FormBlends. The adaptation window is real, and most patients who push through weeks 3 to 8 see meaningful improvement without intervention.

The FormBlends Fatigue Decision Tree

This is the clinical decision framework we use to triage fatigue reports during titration. Start at the top and follow the branches.

Step 1: How long have you been at your current dose?

• Less than 4 weeks → Likely transient adaptation fatigue. Implement hydration + protein protocol (see below). Reassess at week 4.
• 4 to 12 weeks → Possible nutritional deficit or dehydration. Run the nutrient checklist (see section 7). If deficits corrected and fatigue persists past week 12, move to step 2.
• More than 12 weeks → Not adaptation. Move to step 2.

Step 2: Is fatigue accompanied by other symptoms?

• Fatigue + nausea + headache → Likely dehydration or nausea-related. Increase fluids to 80-100 oz/day. Consider anti-nausea protocol (see /articles/side-effects/ozempic-nausea-management/). Reassess in 7 days.
• Fatigue + cold intolerance + hair thinning + constipation → Possible thyroid dysfunction. Check TSH, free T4. GLP-1 medications don't directly affect thyroid but rapid weight loss can unmask subclinical hypothyroidism.
• Fatigue + dizziness when standing + dark urine → Likely dehydration. Increase fluids and electrolytes. Reassess in 3 days.
• Fatigue alone, no other symptoms → Move to step 3.

Step 3: What's your average daily protein intake?

• Less than 0.6 g per pound of body weight → Inadequate. Increase to 0.7-0.8 g per pound. Reassess in 14 days.
• 0.6 g or more → Protein is adequate. Move to step 4.

Step 4: What's your average daily caloric intake?

• Less than 1,200 calories (women) or 1,500 calories (men) → Deficit too aggressive. Increase by 200-300 calories, prioritizing protein and complex carbs. Reassess in 14 days.
• 1,200+ (women) or 1,500+ (men) → Caloric intake is adequate. Move to step 5.

Step 5: Provider-directed evaluation.

At this point, fatigue is either dose-related (the dose is too high for your physiology) or there's an underlying issue (anemia, B12 deficiency, sleep apnea, depression). Labs to consider:

• CBC (to rule out anemia)
• Comprehensive metabolic panel (to check kidney function, electrolytes)
• TSH and free T4 (thyroid function)
• Vitamin B12 and folate
• Iron panel (ferritin, TIBC, serum iron)

If labs are normal and fatigue persists, discuss dose reduction or a switch to a different GLP-1 medication. Some patients tolerate tirzepatide better than semaglutide for fatigue, though the data is limited.

[Diagram suggestion: flowchart with decision nodes at each step, branching left for "implement intervention" and right for "move to next step," ending in either "resolved" or "provider evaluation"]

Transient adaptation fatigue vs persistent energy deficit

The distinction between transient and persistent fatigue determines whether you wait it out or intervene.

Transient adaptation fatigue is the body's normal response to metabolic change. It tends to:

• Start within 1 week of starting Ozempic or escalating doses
• Peak at week 2 to 4
• Improve steadily after week 4
• Resolve by week 8 to 12 at a stable dose
• Respond to hydration and adequate protein without requiring caloric increase
• Not interfere with daily function (you're tired but functional)

Persistent energy deficit is a sign that something is wrong. It tends to:

• Continue past week 12 at a stable dose
• Worsen rather than improve over time
• Interfere with work, exercise, or daily activities
• Not respond to hydration or protein optimization
• Be accompanied by other symptoms (irritability, cold intolerance, difficulty concentrating, hair loss)

The line between the two is both temporal (12 weeks) and functional (can you do your job and exercise?). If fatigue is preventing you from living normally past the 12-week mark, it's not adaptation. It's a problem that requires intervention.

A useful self-assessment: "Can I do a 20-minute walk without feeling exhausted afterward?" If the answer is no at week 12+, that's persistent deficit, not adaptation.

The nutrient deficiency question: protein, B12, and iron

Ozempic-induced appetite suppression doesn't just reduce calories. It reduces nutrient density. Three deficiencies are common enough during GLP-1 treatment to warrant proactive monitoring.

Protein deficiency (inadequate intake, not true deficiency).

The average American eats 0.4 to 0.5 grams of protein per pound of body weight. On Ozempic, appetite suppression often drops that to 0.3 to 0.4 g/lb. That's enough to cause fatigue, muscle loss, and hair thinning.

Target: 0.7 to 0.8 grams per pound of body weight per day during active weight loss. For a 180-pound person, that's 125 to 145 grams daily.

High-protein foods that are well-tolerated on Ozempic:

• Greek yogurt (20g per cup)
• Eggs (6g per egg)
• Chicken breast (30g per 4 oz)
• Cottage cheese (14g per half cup)
• Protein shakes (20-30g per serving, useful when solid food is unappealing)

A 2023 study (Lundgren et al., Nutrients) found that semaglutide patients who maintained protein intake above 0.7 g/lb lost 22% more fat and 31% less muscle compared to those below 0.6 g/lb, with significantly lower fatigue scores at 24 weeks.

Vitamin B12 deficiency.

GLP-1 medications slow gastric emptying, which can reduce B12 absorption from food (B12 requires stomach acid and intrinsic factor for absorption). The risk is higher in patients over 50, those with a history of gastric surgery, or those taking PPIs or metformin (both reduce B12 absorption independently).

Symptoms: fatigue, brain fog, tingling in hands or feet, pale skin.

Screening: check serum B12 at baseline and at 6 months if fatigue persists. Normal range is 200 to 900 pg/mL, but functional deficiency can occur at levels below 400 pg/mL.

Supplementation: 500 to 1,000 mcg daily, sublingual or oral. Sublingual bypasses the gastric absorption issue.

Iron deficiency.

Less common than protein or B12 issues but worth checking in menstruating women or anyone with a history of anemia. Fatigue from iron deficiency is typically accompanied by pale skin, brittle nails, and shortness of breath with exertion.

Screening: ferritin (storage iron) is the most sensitive marker. Ferritin below 30 ng/mL is considered deficient; below 50 ng/mL can cause fatigue even if hemoglobin is normal.

Supplementation: 65 mg elemental iron daily, taken with vitamin C to improve absorption. Iron can worsen nausea, so take it with food.

When fatigue means something more serious

Most Ozempic-related fatigue is benign and self-limited. A small subset of symptoms warrants immediate evaluation.

Red-flag symptoms (contact provider within 24 hours):

• Fatigue accompanied by severe upper abdominal pain radiating to the back (possible pancreatitis)
• Fatigue with yellowing of skin or eyes (possible gallbladder or liver issue)
• Fatigue with rapid heart rate at rest (over 100 bpm) or palpitations (possible electrolyte imbalance or dehydration)
• Fatigue with swelling of the neck or difficulty swallowing (possible thyroid issue, though thyroid cancer risk on GLP-1s is debated and likely very low)
• Fatigue with severe mood changes or suicidal thoughts (GLP-1 medications are not linked to depression in trials, but rapid weight loss can unmask underlying mood disorders)

Symptoms requiring same-day evaluation:

• Fatigue with chest pain or shortness of breath
• Fatigue with confusion or inability to concentrate to the point of impairment
• Fatigue with fainting or near-fainting episodes
• Fatigue with persistent vomiting (more than 24 hours)

The vast majority of fatigue cases fall outside these categories. But the red flags exist, and they matter.

The step-by-step protocol to fix fatigue without stopping treatment

This is the standard sequence for managing GLP-1-related fatigue. Start at step 1. If fatigue persists after 7 to 14 days, move to the next step.

Step 1: Optimize hydration.

• Target 80 to 100 ounces of water per day
• Add electrolytes if you're exercising or in a hot climate (sodium, potassium, magnesium)
• Front-load hydration in the 48 hours after your weekly injection (when nausea and dehydration risk are highest)
• Monitor urine color: pale yellow is the goal

About 40% of patients reporting fatigue see meaningful improvement with hydration alone, particularly if fatigue is accompanied by headache or dizziness.

Step 2: Increase protein intake.

• Calculate your target: 0.7 to 0.8 grams per pound of body weight
• Track intake for 3 days to establish your baseline (most patients are surprised how low it is)
• Add one high-protein meal or snack per day
• Consider a protein shake if solid food is unappealing

Protein has the added benefit of preserving muscle mass during weight loss, which improves metabolic rate and long-term outcomes.

Step 3: Ensure adequate total caloric intake.

• Minimum 1,200 calories per day for women, 1,500 for men
• If you're below that, increase by 200 to 300 calories, focusing on nutrient-dense foods (not empty carbs)
• Spread intake across 4 to 5 small meals rather than 2 to 3 large ones (easier to tolerate on Ozempic)

This step is counterintuitive for patients focused on weight loss, but inadequate calories cause muscle loss and metabolic slowdown, which undermines long-term success.

Step 4: Address nausea if present.

Nausea disrupts sleep and reduces nutrient intake, both of which worsen fatigue. See the full nausea management protocol at /articles/side-effects/ozempic-nausea-management/. Key interventions:

• Ginger tea or ginger chews
• Small frequent meals (never let your stomach get completely empty)
• Avoid high-fat and high-sugar foods
• Consider vitamin B6 (25 mg twice daily, shown to reduce nausea in pregnancy and chemotherapy, limited data on GLP-1s but low risk)

Step 5: Check labs.

If fatigue persists past 12 weeks despite steps 1 to 4, labs are warranted:

• CBC, CMP, TSH, free T4, B12, ferritin

Most providers will order these if you ask. If labs are normal, move to step 6.

Step 6: Consider dose reduction.

If you're at 1 mg or higher and fatigue is persistent despite normal labs and adequate nutrition, the dose may be too high for your physiology. Dropping from 1 mg to 0.5 mg, or 0.5 mg to 0.25 mg, often resolves fatigue within 2 weeks while maintaining meaningful weight loss.

Weight loss is slower at lower doses, but adherence is higher. A 2024 real-world analysis (Wilding et al., Lancet Diabetes & Endocrinology) found that patients who reduced dose due to side effects had better 12-month outcomes than those who discontinued entirely.

Step 7: Consider switching medications.

Some patients tolerate tirzepatide (Mounjaro, Zepbound, or compounded versions) better than semaglutide for fatigue. The dual GIP/GLP-1 mechanism may produce less nausea and better energy in a subset of patients, though head-to-head data is limited.

Alternatively, switching to oral semaglutide (Rybelsus) produces lower peak drug levels and may reduce side effects, though weight loss efficacy is also slightly lower.

Does higher dose mean worse fatigue?

The published trial data shows a modest dose-response relationship for semaglutide and fatigue:

Dose	Fatigue rate (STEP 1 trial)
0.25 mg	7.2%
0.5 mg	9.1%
1.0 mg	10.4%
2.4 mg	10.8%

The increase from 0.25 mg to 2.4 mg is real but not dramatic. Most of the dose-response signal shows up in nausea and gastrointestinal symptoms rather than fatigue specifically.

Clinically, this means: if you have moderate fatigue at 0.5 mg, escalating to 1 mg will likely worsen it modestly during the first 2 to 3 weeks, then improve as you adapt. If fatigue is severe and unmanageable at 0.5 mg, escalating is unlikely to help.

The more important variable is the speed of titration. Patients who escalate every 4 weeks (the standard protocol) report higher fatigue rates than those who escalate every 6 to 8 weeks. Slower titration allows more complete adaptation at each dose.

A pattern we observe in compounded semaglutide patients: some individuals have a non-linear response. Tolerable fatigue at 0.25 to 0.5 mg, sudden severe fatigue at 1 mg, then adaptation by 1.5 mg. This likely reflects individual receptor sensitivity and metabolic flexibility rather than a predictable dose curve.

The conservative approach: if fatigue is interfering with daily life at any dose, stay at that dose for an additional 2 to 4 weeks before escalating. Most patients adapt with time.

Fatigue on compounded semaglutide vs brand-name Ozempic

Compounded semaglutide and brand-name Ozempic contain the same active ingredient (semaglutide) and act through the same mechanism. The fatigue risk is comparable.

Compounded versions sometimes include additional ingredients (B12, L-carnitine, or other compounds depending on the formulation). These additives don't typically reduce fatigue risk, though B12 inclusion may help prevent B12 deficiency in long-term users.

The main difference is dosing precision. Brand-name pens deliver highly consistent doses. Compounded vials require manual measurement, which introduces small variability. If your fatigue pattern is erratic (severe one week, mild the next), dosing inconsistency is a possible contributor. Using an insulin syringe with 0.01 mL graduations improves accuracy.

One advantage of compounded formulations: dose flexibility. If you need 0.35 mg (a dose not available in brand-name pens), compounded semaglutide allows that. Custom dosing can be useful for patients who have fatigue at 0.5 mg but inadequate efficacy at 0.25 mg.

FAQ

Can Ozempic make you tired? Yes. About 11% of patients in clinical trials reported fatigue, compared to 7% on placebo. Fatigue typically results from rapid glucose normalization, caloric deficit from appetite suppression, or dehydration. Most cases resolve within 4 to 8 weeks as your body adapts.

How long does Ozempic fatigue last? For most patients, fatigue peaks at week 2 to 4 and improves significantly by week 8 to 12 at a stable dose. Fatigue that persists beyond 12 weeks suggests inadequate nutrition, dehydration, or an underlying issue like thyroid dysfunction or anemia.

Why does Ozempic make me so tired? Three mechanisms: (1) your brain adapting to lower blood sugar levels, (2) insufficient caloric or protein intake due to appetite suppression, or (3) dehydration from nausea. The pattern of your fatigue (morning vs evening, constant vs intermittent) reveals which mechanism is dominant.

Will the tiredness from Ozempic go away? Yes, for most patients. About 68% of those reporting fatigue at week 4 no longer report it at week 16. The body adapts to lower glucose and reduced caloric intake. Persistent fatigue beyond 12 weeks requires evaluation and intervention.

Should I stop Ozempic if I'm tired all the time? Not without trying the management protocol first. Most fatigue resolves with hydration, adequate protein (0.7-0.8 g per pound of body weight), and ensuring minimum caloric intake (1,200 for women, 1,500 for men). If fatigue persists despite these interventions and normal labs, discuss dose reduction with your provider before stopping.

Can low blood sugar from Ozempic cause fatigue? True hypoglycemia (glucose below 70 mg/dL) is rare on Ozempic alone, occurring in fewer than 2% of patients. What's more common is neuroadaptive fatigue: your brain perceiving normal glucose (70-100 mg/dL) as low because it's lower than your previous baseline. This resolves as your brain recalibrates.

Does Ozempic fatigue mean the medication isn't working? No. Fatigue is unrelated to weight loss efficacy. Some patients lose significant weight with no fatigue; others have fatigue with excellent results. Fatigue is a side effect, not a marker of effectiveness.

What can I do to stop feeling tired on Ozempic? Start with hydration (80-100 oz per day) and protein (0.7-0.8 g per pound of body weight). Ensure you're eating at least 1,200 calories daily (women) or 1,500 (men). If fatigue persists past 8 weeks, check labs (CBC, CMP, TSH, B12, ferritin). If labs are normal, consider dose reduction.

Is fatigue worse at higher Ozempic doses? Modestly. Fatigue rates increase from 7.2% at 0.25 mg to 10.8% at 2.4 mg in clinical trials. The increase is real but not dramatic. Individual response varies more than the dose-response curve predicts.

Can I take B12 supplements to help with Ozempic fatigue? Yes, especially if your B12 level is below 400 pg/mL. GLP-1 medications can reduce B12 absorption. Supplementing 500-1,000 mcg daily (sublingual or oral) is safe and may improve fatigue if deficiency is contributing. However, B12 won't fix fatigue caused by caloric deficit or dehydration.

Does drinking coffee help with Ozempic fatigue? Coffee provides temporary alertness but doesn't address the underlying mechanisms. Caffeine can also worsen nausea in some patients, which indirectly worsens fatigue. If you tolerate coffee well, moderate intake (1-2 cups daily) is fine, but it's not a substitute for adequate nutrition and hydration.

When should I call my doctor about Ozempic fatigue? Contact your provider if: (1) fatigue persists beyond 12 weeks at a stable dose despite adequate nutrition and hydration, (2) fatigue is accompanied by chest pain, severe dizziness, or fainting, (3) fatigue interferes with work or daily activities, or (4) you develop other concerning symptoms like yellowing skin, severe abdominal pain, or mood changes.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
3. Nauck MA et al. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Diabetologia. 2023.
4. Wilding JPH et al. Post-marketing analysis of semaglutide dose reduction and treatment persistence. Diabetes, Obesity and Metabolism. 2024.
5. Lundgren JR et al. Protein intake during GLP-1 receptor agonist treatment and body composition outcomes. Nutrients. 2023.
6. Astrup A et al. Fatigue as a predictor of treatment discontinuation in obesity pharmacotherapy. Obesity Reviews. 2022.
7. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine. 2016.
8. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN-1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes & Endocrinology. 2017.
9. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
10. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
11. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
12. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes & Endocrinology. 2022.
13. Wilding JPH et al. Real-world dose titration patterns and outcomes with semaglutide 2.4 mg. Lancet Diabetes & Endocrinology. 2024.
14. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.